Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients

International Journal of Clinical Pharmacy
Soubra LamaFattouh Youssef

Abstract

Background Current guidelines recommend a low-density lipoprotein cholesterol goal of <1.8 mmol/L (<70 mg/dL) and a non high-density lipoprotein cholesterol (non-HDL-C) goal of <2.6 mmol/L (<00 mg/dL) for coronary artery disease (CAD) patients. Objective This study aimed to describe real-life statin prescription strategies and to assess their effectiveness in terms of LDL-C and non-HDL-C goals attainment in a cohort of CAD patients. Setting Outpatient cardiology specialty clinics located in main Lebanese cities. Methods This is a retrospective crosssectional study. Eligible patients were those who had established CAD, treated with statins and having complete follow-up lipid panel at least 3 months from statin prescription. The following statin prescription strategies were considered in data analysis: prescription of different intensity statin as monotherapy, prescription of a statin in combination with: a low fat diet, another lipid-altering agent and another lipidaltering agent plus a low fat diet. Main outcome measure LDL-C goal attainment for each of the statin prescription strategy. Results Of the 423 CAD statin-treated patients, only 38.5 and 36.6% attained their recommended LDL-C and non-HDL-C goals, respectively. Using a...Continue Reading

References

Feb 24, 2000·The Medical Clinics of North America·D R Illingworth
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Aug 18, 2004·Circulation·Carl J Vaughan, Antonio M Gotto
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Nov 18, 2005·The American Journal of Cardiology·Michael H Davidson
Dec 29, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Kheng-Thye HoDon Yin
Nov 12, 2010·Lancet·UNKNOWN Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative GroupRory Collins
Nov 16, 2010·The Canadian Journal of Cardiology·Shaun G GoodmanUNKNOWN DYSIS Canadian Investigators
Nov 26, 2010·International Journal of Clinical Practice·T A Jacobson
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Nov 15, 2011·Current Pharmaceutical Design·Yessica-Haydee Gomez SandovalStella S Daskalopoulou
Jan 15, 2013·Journal of the American Heart Association·Peter H JonesKamlesh M Thakker
Nov 12, 2013·Lipids in Health and Disease·Ioanna XanthopoulouDimitrios Alexopoulos
Nov 19, 2013·Journal of the American College of Cardiology·Neil J StoneUNKNOWN American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Jun 24, 2014·Current Pharmaceutical Design·Kim PhanStella S Daskalopoulou
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Dec 25, 2015·Journal of Clinical Lipidology·Terry A JacobsonUNKNOWN NLA Expert Panel

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.